Yanlin Bian

A CXCR4/PD-L1 Bispecific Nanobody Engineered for Tumor Microenvironment Retention Mediates Sustained Synergy with Chemotherapy via Remodeling Immunity in TNBC

Shuyi Xu, Hai Hu, Yifan Li, Jiawei Zhang et autres

Background: The efficacy of chemotherapy in triple-negative breast cancer (TNBC) is limited by intrinsic resistance and the tumor microenvironment (TME). Accumulating evidence reveals a mechanistic connection between programmed death-ligand 1 (PD-L1) and c-x-c motif chemokine receptor 4 (CXCR4), which dominate stroma barriers, …

cn (code pays fourni par la source)

Dual Epitope Engagement Enables Broad-Spectrum Neutralization of SARS-CoV-2 Variants by Bispecific Antibody 9A6-6C3

Jianwei Zhu, Yunji Liao, Haoneng Tang, Hang Ma et autres

cn (code pays fourni par la source)

Unveiling the Accurate Site-Specific N- and O-Glycosylation of Hyperglycosylated Erythropoietin Drugs by an Integrated Approach

Shuye Wu, Ji-Hong Lu, Nafisa Tursumamat, Qiannan Liu et autres

Hyperglycosylated proteins with a high sialic acid content show great promise in the development of long-acting biotherapeutics. However, their structural complexity and heterogeneity pose significant challenges to traditional analytical methods, which often fail to provide comprehensive glycan information across all glycosylation sites, …

cn, us, de (code pays fourni par la source)

Generating potent and persistent antitumor immunity via affinity-tuned CAR-T cells targeting mesothelin

Yali Yue, Junjun Liu, Hang Ma, Zhidi Pan et autres

cn (code pays fourni par la source)

Rapid restoration of potent neutralization activity against the latest Omicron variant JN.1 via AI rational design and antibody engineering

Yunji Liao, Hang Ma, Zhenyu Wang, Shusheng Wang et autres

The rapid evolution of the viral genome has led to the continual generation of new variants of SARS-CoV-2. Developing antibody drugs with broad-spectrum and high efficiency is a long-term task. It is promising but challenging to develop therapeutic neutralizing antibodies (nAbs) through …

cn, ca, us, no (code pays fourni par la source)

ABTrans: A Transformer-based Model for Predicting Interaction between Anti-Aβ Antibodies and Peptides

Yuhong Su, Xincheng Zeng, Lingfeng Zhang, Yanlin Bian et autres

cn, ca (code pays fourni par la source)

The immunotoxin targeting PRLR increases tamoxifen sensitivity and enhances the efficacy of chemotherapy in breast cancer

Jiawei Zhang, Junjun Liu, Yali Yue, Lei Wang et autres

BACKGROUND: Though tamoxifen achieves success in treating estrogen receptor α (ERα)-positive breast cancer, the followed development of tamoxifen resistance is a common challenge in clinic. Signals downstream of prolactin receptor (PRLR) could synergize with ERα in breast cancer progression. However, the potential …

cn, us (code pays fourni par la source)

T cell-redirecting antibody for treatment of solid tumors via targeting mesothelin

Junjun Liu, Zhidi Pan, Yali Yue, Shusheng Wang et autres

cn (code pays fourni par la source)

Characterization of a novel T cell-engaging bispecific antibody for elimination of L1CAM-positive tumors

Yuan Yuan, Junyan Li, Jie Chen, Lei Han et autres

Neural cell adhesion molecule L1 (L1CAM) is a cell-surface glycoprotein involved in cancer occurrence and migration. Up to today, L1CAM-targeted therapy appeared limited efficacy in clinical trials although quite a few attempts by monoclonal antibody (mAb) or chimeric antigen receptor T-cell therapy …

cn (code pays fourni par la source)

Neutralization of SARS-CoV-2 infection by antibodies targeting diverse epitopes

Shusheng Wang, Yunji Liao, Kaiyong Yang, Hang Ma et autres

cn (code pays fourni par la source)

Binding domain on CD22 molecules contributing to the biological activity of T cell-engaging bispecific antibodies

Jie Chen, Zhidi Pan, Lei Han, Junjun Liu et autres

CD22, as the B-cell malignancies antigen, has been targeted for immunotherapies through CAR-T cells, antibody-drug conjugates (ADCs) and immunotoxins via interaction of antibodies with binding domains on the receptor. We hypothesized that avidity and binding domain of antibody to target cells may …

cn (code pays fourni par la source)

Long-term passaging of pseudo-typed SARS-CoV-2 reveals the breadth of monoclonal and bispecific antibody cocktails

Hang Ma, Huifang Zong, Junjun Liu, Yali Yue et autres

cn (code pays fourni par la source)